Orforglipron Tracker App
Track Your Orforglipron Protocol
Orforglipron is an oral glp-1 (lilly) used in ATTAIN with 14.7% weight loss at 36 weeks. Shotlee is the free app to track your complete Orforglipron protocol — doses, side effects, weight, and labs.
What Is Orforglipron?
Orforglipron is an oral glp-1 (lilly) used in ATTAIN with 14.7% weight loss at 36 weeks. Shotlee is the free app to track your complete Orforglipron protocol — doses, side effects, weight, and labs.
Shotlee tracks every aspect of your Orforglipron protocol: injection dates, doses, sites, side effects, weight changes, and lab results. Whether you are starting or optimizing, clean data makes better decisions.
What to Track in Shotlee
Build a complete Orforglipron protocol record from day one.
How to Track Your Orforglipron Protocol
Orforglipron Key Facts
Protocol FAQs
A once-daily oral small-molecule GLP-1 receptor agonist from Eli Lilly. No injections, no fasting requirements. Phase 3 trials show up to 12.4% weight loss. FDA approval expected mid-2026.
Open Shotlee, select orforglipron, log your daily tablet, and track weight and side effects. Daily reminders keep you consistent.
Yes — orforglipron tracking is completely free forever. Premium AI features are available optionally.
Open the Shotlee app, navigate to the dose logging screen, select Orforglipron as your medication, and enter the dose amount, injection site, and time. Shotlee stores all entries with timestamps and lets you view your complete dose history, adherence rate, and missed dose alerts. The app is free to download and use.
The most important side effects to track include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), injection site reactions, appetite changes, energy levels, and any unusual symptoms. Log these daily in Shotlee so you can share accurate trend data with your healthcare provider at your next visit.
Most patients begin noticing appetite changes within the first one to two weeks. Measurable weight loss typically becomes apparent by weeks four to eight, depending on the dose titration schedule and individual metabolic response. Track your weekly weight in Shotlee to visualize your personal response curve over time.
Track Your Orforglipron Protocol in Shotlee
Free dose logs, side effect tracking, weight trends, and lab results — all in one app.
📚References & sources
Latest on Orforglipron
New Weight Loss Pill Beats Oral Ozempic in Major Clinical Trial
A recent Phase 3 clinical trial indicates that orforglipron offers superior blood sugar control and weight loss compared to oral semaglutide, though side effects remain a consideration.
9 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read